Patent US2513240A successfully refreshed from Google Patents.
Patent US4935204A successfully refreshed from Google Patents.
US4935204A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process and device for the specific adsorption of heparin
Assignee: B Braun Medical Inc
•
Filing: 1988-11-14
•
Granted: 1990-06-19
•
Expires: 2008-11-14
Abstract
Abstract A process for the specific adsorption of heparin and other heparin-like substances which comprises flowing a buffered solution of whole blood, from which corpuscular blood constituents have been removed, plasma and/or solutions containing whole blood or plasma through an adsorber capsule containing a medium that adsorbs heparin and other heparin-like substances at an acid pH, preferably in the range of 4.0 to 5.5. Preferably, the process is carried out in a closed, extracorporeal circulation and the medium possesses anion exchange resin properties.
Inventors
- 👤 Dietrich Seidel
- 👤 Wolfgang Feller
- 👤 Gerhard Rosskopf
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 17:58
CPC Classifications
A; A61; A61M; A61M1/00; A61M1/36; A61M1/3679; A61M1/34; A61M1/3472; A61M1/3486; A61M1/3672; A61M1/3675; Y; Y10; Y10S; Y10S435/00; Y10S435/803
Claims Analysis
Total Claims: 37
Claim 1
Independent Claim
142 words
A process for the specific adsorption of heparin and other heparin-like substances from whole blood, plasma or diluted solutions of whole blood or plasma, which comprises the steps of: (a) providing a solution comprising whole blood, plasma or diluted solutions of whole blood or plasma containing heparin or other heparin-like substances; (b) separating corpuscular blood constituents from the solution, if necessary; (c) buffering the solution by means of a buffer to a pH in the range of about 4.0 to about 5.2; (d) flowing the buffered solution through an adsorber capsule containing a basic medium which adsorbs heparin and other heparin-like substances thereby removing heparin and other heparin-like substances from the buffered solution; and (e) adjusting the pH of the buffered solution to physiological conditions appropriate to a desired subject such that the solution may be infused safely into the desired subject.
Claim 2
Dependent Claim
142 words
A process for the specific adsorption of heparin and other heparin-like substances from whole blood, plasma or diluted solutions of whole blood or plasma, which comprises the steps of: (a) providing a solution comprising whole blood, plasma or diluted solutions of whole blood or plasma containing heparin or other heparin-like substances; (b) separating corpuscular blood constituents from the solution, if necessary; (c) buffering the solution by means of a buffer to a pH in the range of about 4.0 to about 5.2; (d) flowing the buffered solution through an adsorber capsule containing a basic medium which adsorbs heparin and other heparin-like substances thereby removing heparin and other heparin-like substances from the buffered solution; and (e) adjusting the pH of the buffered solution to physiological conditions appropriate to a desired subject such that the solution may be infused safely into the desired subject.
Claim 3
Dependent Claim
55 words
The process according to claim 1 further comprising the steps of: (a) recombining the corpuscular blood constitutents with the solution of step (e) adjusted to the pH appropriate to the physiological conditions of a desired subject; and (b) infusing the recombined solution into the desired subject or returning the recombined solution to regular stored blood.
Claim 4
Dependent Claim
17 words
The process according to claim 1 wherein the process is carried out in a closed, extracorporeal circulation.
Claim 5
Dependent Claim
35 words
The process according to claim 1 wherein the adsorber capsule comprises a sterilized, cylindrically shaped capsule containing a cap and bottom equipped with central intake and outlet nozzles and one or more circular double screens.
Claim 6
Dependent Claim
18 words
The process according to claim 4 wherein the screens have a mesh between about 50 to 100 μm.
Claim 7
Dependent Claim
27 words
The process according to claim 1 wherein the buffered solution flows through the adsorber capsule at a rate of flow between about 60 ml/hr and 25 L/hr.
Claim 8
Dependent Claim
33 words
The process according to claim 1 wherein the related heparin substances are chosen from the group consisting of heparin fractions, heparin derivatives, heparin fragments, heparinoids, and polyanionic glycosamino glycan containing sulfate ester groups.
Claim 9
Dependent Claim
28 words
The process according to claim 1 wherein the separation of the solution from corpuscular blood constituents is achieved through the use of one or more membrane plasma filters.
Claim 10
Dependent Claim
26 words
The process according to claim 1 wherein the separation of the solution from the corpuscular blood constituents is achieved through the use of a filter cascade.
Claim 11
Dependent Claim
12 words
The process according to claim 1 wherein the buffer is sodium acetate.
Claim 12
Dependent Claim
18 words
The process according to claim 1 wherein the buffered solution has a pH between about 4.7 and 5.2.
Claim 13
Dependent Claim
26 words
The process according to claim 1 wherein the buffered solution flows through the absorber capsule at a rate of flow between about 1.5 and 12 L/hr.
Claim 14
Dependent Claim
39 words
The process according to claim 1 wherein the medium of the adsorber capsule is selected from the group consisting of an ion exchange resin acting as an anion exchanger and a macroporous anion exchange resin possessing basic anchor groups.
Claim 15
Dependent Claim
17 words
The process according to claim 1 wherein the adsorber capsule is equipped with an adsorption filter cartridge.
Claim 16
Dependent Claim
51 words
The process according to claim 1 wherein the adsorber capsule contains an adsorption filter cartridge comprising a supporting screen with a solid or hollow core, around which screen is wound a fiber mat on a cellulose base that possesses anion exchange properties thereby capable of acting as an active adsorber material.
Claim 17
Dependent Claim
25 words
The process according to claim 1 wherein the adsorber capsule is filled with a gel possessing anion exchange properties and which is moistened with water.
Claim 18
Dependent Claim
38 words
The process according to claim 1 wherein the adsorber capsule has a heparin capacity between about 10,000 and 100,000 IU of heparin, and a capacity for heparinoids, heparin fractions, heparin fragments and heparin derivatives of about 2 grams.
Claim 19
Dependent Claim
44 words
The process according to claim 1 wherein the adsorber capsule is sterilized by a method selected from the group consisting of exposure to gamma rays, treatment with ethylene oxide and heat treatment prior to the flowing of the buffered solution through the adsorber capsule.
Claim 20
Dependent Claim
128 words
A process for the specific adsorption of heparin and other heparin-like substances from whole blood, plasma or diluted solutions of whole blood or plasma, which comprises the steps of: (a) providing a solution comprising plasma or diluted solutions of plasma containing heparin or other heparin-like substances; (b) separating corpuscular blood constituents from the solution, if necessary; (c) buffering the solution by means of a buffer to a pH in the range of about 4.7 to about 5.2; (d) flowing the buffered solution through an adsorber capsule containing a basic anion exchanger adsorption material which adsorbs heparin and other heparin-like substances; (e) adjusting the pH of the buffered solution to physiological conditions appropriate to a desired subject, such that a solution by safely be infused into the desired subject.
Claim 21
Dependent Claim
128 words
A process for the specific adsorption of heparin and other heparin-like substances from whole blood, plasma or diluted solutions of whole blood or plasma, which comprises the steps of: (a) providing a solution comprising plasma or diluted solutions of plasma containing heparin or other heparin-like substances; (b) separating corpuscular blood constituents from the solution, if necessary; (c) buffering the solution by means of a buffer to a pH in the range of about 4.7 to about 5.2; (d) flowing the buffered solution through an adsorber capsule containing a basic anion exchanger adsorption material which adsorbs heparin and other heparin-like substances; (e) adjusting the pH of the buffered solution to physiological conditions appropriate to a desired subject, such that a solution by safely be infused into the desired subject.
Claim 22
Dependent Claim
33 words
The process according to claim 19 wherein the other heparin-like substances are selected from the group consisting of heparin fractions, heparin fragments, heparin derivatives, heparinoids and polyanionic glycosamino glycan containing sulfate ester groups.
Claim 23
Dependent Claim
55 words
The process according to claim 19 further comprising the steps of: (a) recombining the corpuscular blood constituents with the solution of step (e) adjusted to the pH appropriate to the physiological conditions of a desired subject; and (b) infusing the recombined solution into the desired subject or returning the recombined solution to regular stored blood.
Claim 24
Dependent Claim
39 words
The process according to claim 19 wherein the medium of the adsorber capsule is selected from the group consisting of an ion exchange resin acting as an anion exchanger and a macroporous anion exchange resin possessing basic anchor groups.
Claim 25
Dependent Claim
17 words
The process according to claim 19 wherein the process is carried out in a closed, extracorporeal circulation.
Claim 26
Dependent Claim
35 words
The process according to claim 19 wherein the adsorber capsule comprises a sterilized, cylindrical shaped capsule containing a cap and bottom equipped with central intake and outlet nozzles and one or more circular double screens.
Claim 27
Dependent Claim
18 words
The process according to claim 24 wherein the screens have a mesh between about 50 to 100 μm.
Claim 28
Dependent Claim
27 words
The process according to claim 19 wherein the buffered solution flows through the adsorber capsule at a rate of flow between about 60 ml/hr and 25 L/hr.
Claim 29
Dependent Claim
19 words
The process according to claim 19 wherein the solution may be whole blood or diluted solutions of whole blood.
Claim 30
Dependent Claim
33 words
The process according to claim 19 wherein the related haparin substances are chosen from the group consisting of heparin fractions, heparin derivatives, heparin fragments, heparinoids, and polyanionic glycosamino glycan containing sulfate ester groups.
Claim 31
Dependent Claim
28 words
The process according to claim 19 wherein the separation of the solution from corpuscular blood constituents is achieved through the use of one or more membrane plasma filters.
Claim 32
Dependent Claim
26 words
The process according to claim 19 wherein the separation of the solution from the corpuscular blood constituents is achieved through the use of a filter cascade.
Claim 33
Dependent Claim
12 words
The process according to claim 19 wherein the buffer is sodium acetate.
Claim 34
Dependent Claim
26 words
The process according to claim 19 wherein the buffered solution flows through the adsorber capsule at a rate of flow between about 1.5 and 12 L/hr.
Claim 35
Dependent Claim
17 words
The process according to claim 19 wherein the adsorber capsule is equipped with an adsorption filter cartridge.
Claim 36
Dependent Claim
50 words
The process according to claim 19 wherein the adsorber capsule contains an adsorption filter cartridge comprising a supporting screen with a solid or hollow core, around which screen is wound a fiber mat on a cellulose base which possesses anion exchange properties capable of acting as an active adsorber material.
Claim 37
Dependent Claim
25 words
The process according to claim 19 wherein the adsorber capsule is filled with a gel possessing anion exchange properties and which is moistened with water.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-06-18 | 1993-12-18 | 1994-06-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-06-18 | 1997-12-18 | 1998-06-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-06-18 | 2001-12-18 | 2002-06-19 | $7700.00 | Window Closed / Lapsed |